Cerevel Therapeutics Holdings (STU:673) Additional Paid-In Capital : €1,930.19 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Additional Paid-In Capital?

Cerevel Therapeutics Holdings's quarterly additional paid-in capital increased from Sep. 2023 (€1,442.23 Mil) to Dec. 2023 (€1,900.53 Mil) and increased from Dec. 2023 (€1,900.53 Mil) to Mar. 2024 (€1,930.19 Mil).

Cerevel Therapeutics Holdings's annual additional paid-in capital increased from Dec. 2021 (€1,058.41 Mil) to Dec. 2022 (€1,402.67 Mil) and increased from Dec. 2022 (€1,402.67 Mil) to Dec. 2023 (€1,900.53 Mil).

Cerevel Therapeutics Holdings Additional Paid-In Capital Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Additional Paid-In Capital Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

289.90

637.39

1,058.41

1,402.67

1,900.53

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial													1,401.04	1,403.81	1,442.23	1,900.53	1,930.19

Cerevel Therapeutics Holdings Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cerevel Therapeutics Holdings Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines